SNPX News and Press, Synaptogenix Inc. From 07/14/23

2023-07-14 06:21:00 ET 3 Questions About Penny Stocks: Answered for 2023 Penny stocks, often undervalued by the mainstream investment world, present a unique opportunity for those willing to explore the less trodden paths of the financial markets. As we navigate through 2023, the penn...

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience PR Newswire Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint...

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities PR Newswire Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients Maintains strong finan...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the t...

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease PR Newswire NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an eme...

Summary Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer’s disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has some effect, and has a unique mechanism of action. Despite a clear po...

Synaptogenix Announces $15 Million Private Placement with Existing Investors PR Newswire Topline data from NIH-supported Phase 2 clinical trial for advanced AD patients expected during the current quarter NEW YORK , Nov. 18, 2022 /PRNewswire/ -- S...

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 PR Newswire Synaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date Topline data from NIH...

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results PR Newswire Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK , Sept. 28, 2022 /PRNewswire/ -- Synapto...

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data PR Newswire Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ...